NEWS

Biomed Industries to Present Groundbreaking Research at the AD/PD™ 2024 International Conference

San Jose, CA — March 5, 2024 — Biomed Industries, Inc. (Biomed), a leading bio-pharmaceutical company, is set to present three significant papers at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, taking place in Lisbon, Portugal, from March 5th to 9th.

The presentations by Biomed include:

  • • Neurogenesis and Clinical Trials Of NA-831 for Alzheimer's Disease and Major Depressive Disorder
  • • A Phase 3 Clinical Protocol to Study the Safety and Efficacy Of NA-831 in Combination with Lecanemab In Subjects with Early Alzheimer's Disease
  • • What does Amyloid-Beta (Aβ) have to do with Alzheimer's Disease? A History of Failure

AD/PD™ 2024 attracts leading medical and scientific professionals worldwide and serves as a pivotal platform for disseminating cutting-edge research on Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. The conference, renowned for its exploration of disease mechanisms and advancements in treatment, emphasizes prevention and therapy strategies across various neurodegenerative conditions.

“We are excited to present our research on Neurogenesis as a rapidly emerging alternative to current therapeutic approaches in Alzheimer’s Disease. Both the safety and efficacy of NA-831 in our Phase 2 clinical trial has shown results that far exceed the recently FDA approved drugs for AD.” said Lloyd Tran, Founder and CEO of Biomed Industries. He continued: “As it has become increasingly clear that new approaches are needed, we stand at the forefront of this new frontier.”

Biomed will soon conduct a Phase 2B Alzheimer’s Disease (AD) trial and a Phase 3 trial of NA-831 for Major Depressive Disorder (MDD), with plans to seek FDA approval of NA-831 for both indications.


About Biomed Industries, Inc.

Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer's disease and other neurological disorders. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com

CONTACT

Michael Willis
Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Email: media@biomedind.com


For more news, please visit our News page.

For further information about Biomed Industries, Inc., please contact us.